Subject Index

Acoustic neuroma, neurofibromatosis type 2
gamma knife radiosurgery
  complications 103, 105
  hearing outcomes 103, 105
  outcome measures 101
  patient selection 105
  study design 101
  tumor control 101–105
  treatment options 100, 101

Acute complications, radiosurgery
  grading 42
  incidence determination
    dose conformality effects 44
    multivariate analysis 42, 43
    patient characteristics 40, 41
    radiosurgery treatment parameters 40, 41
    side effect types 42
    study design 39, 40, 44
    patient education 44

Anosmia, see Meningioma

Brain tumor metastases
gamma knife radiosurgery
  multiple tumor capabilities 72, 73
  ten or more metastases and dose absorption
    brainstem 78, 80
    optic apparatus 78, 80
  study design 78
  treatment planning, see Positron emission tomography
tumor control probability, multiple tumor treatment prognosis
normal tissue complication probability, effects on survival time 70, 74
study design 68, 69
survival time prediction 68–70, 73, 74
whole-brain irradiation 67, 72, 73

Cancer pain, see Pain

Cavernous malformations
  brainstem lesion surgery 159
  gamma knife radiosurgery
    complications 157, 159
    dose 155
    hemorrhage rate 157, 158
    indications 154
    response 155
    seizure outcomes 157, 158
    study design 155
    imaging 153, 154
    natural history 158

Chordoma, see Skull base chordoma

Cluster headache (CH)
diagnostic criteria 192, 193
gamma knife radiosurgery of trigeminal nerve
  complications 194, 195
  outcomes 191, 192, 194, 195
  study design 191
  pathophysiology 190, 193–195
treatment options 190, 191, 194
Complications, see Acute complications, radiosurgery
Computed tomography (CT)
cisternography for trigeminal neuralgia radiosurgery 182
gamma knife treatment planning accuracy 248, 249
image acquisition 250, 251
overview 247, 248
registration with other imaging techniques 249
validation of frameless positron emission tomography 251–253
stereotactic irradiation device for cat studies 34, 36
Craniopharyngioma, see Sellar-parasellar tumors
CyberKnife radiosurgery
fiducial and skull tracking accuracy, quality assurance
importance 258, 259
monthly test for fiducial tracking accuracy 256
monthly test for skull tracking accuracy 256, 257
outcomes 258
principles 255
trigeminal neuralgia, see Trigeminal neuralgia
Dosimetry, see MAGIC; Polymer gel dosimetry
Fiducial tracking, see CyberKnife radiosurgery
Gamma knife
acoustic neuroma management, see Acoustic neuroma, neurofibromatosis type 2
brain tumor metastasis treatment, see Brain tumor metastases
cavernous malformation management, see Cavernous malformations
cluster headache management, see Cluster headache
development 13
extracranial dose measurement with model C instrument
cancer risks 198
distance influence analysis 205, 211
doses by tissue 199, 200, 210
integral dose influence analysis 204, 211
pathology influence analysis 200–202
phantom data 209, 210
plug influence analysis 206, 208, 211
reference isodose volume influence analysis 204, 211
study design 198, 199
target maximum dose influence analysis 203, 204
treatment time influence analysis 204, 212
glioblastoma multiforme treatment, see Glioblastoma multiforme
low-grade gliomas, see Glioma
pain management, see Pain
pituitary adenoma management, see Pituitary adenoma
polymer gel dosimetry, see MAGIC; Polymer gel dosimetry
principles 39, 197, 198
sellar-parasellar tumor treatment, see Sellar-parasellar tumors
treatment planning imaging, see Computed tomography; Magnetic resonance imaging; Positron emission tomography
inverse treatment planning advantages 265
clinical evaluation 262, 264, 265
morphology-guided planning approach 261, 262
overview 260, 261
vestibular schwannoma management, see Vestibular schwannoma
Gel dosimetry, see Polymer gel dosimetry

Subject Index 281
Glioblastoma multiforme (GBM)
gamma knife radiosurgery
morbidity 94, 96
patient characteristics 92
statistical analysis 93
survival outcomes 93, 94
technique 93
tumor progression management 97, 98
prognostic factors 92, 97
radiobiology 96

Glioma, see also Sellar-parasellar tumors
methionine uptake positron emission
tomography, evaluation of low-grade
gliomas after gamma knife surgery
dosimetry effects on metabolic
course 149
follow-up and data analysis 146
histology 143, 149
magnetic resonance imaging
metabolic activity evaluation 147,
149–151
patient characteristics 144, 145
radiosurgery 145, 146
optic nerve glioma microsurgery versus
gamma knife radiosurgery 10, 11

Hearing preservation
acoustic neuroma gamma knife
radiosurgery in neurofibromatosis
type 2 103, 105
vestibular schwannoma management,
see Vestibular schwannoma

Hypophysectomy, see Pain

Linac radiosurgery, see also CyberKnife
radiosurgery
Novalis system, treatment of meningiomas
combined radiosurgery and
radiotherapy 116
complications 119, 120
intensity-modulated stereotactic
radiosurgery/radiotherapy 121
neurological outcomes 118
patient selection 120
study design 116, 117
tumor control 117–120
vision outcomes 120, 121

Novalis system, treatment of skull
base chordomas
combined radiosurgery and
radiotherapy 83
outcomes 85–89
patient characteristics 83, 85
toxicity 88
treatment planning and delivery 85
principles 39
trigeminal neuralgia management,
see Trigeminal neuralgia

MAGIC
advantages 214
composition and effects on dose response
214, 215, 218, 220, 222
magnetic resonance imaging of absorbed
dose under varying conditions 215,
216, 218, 220
production in the clinic 214, 215, 223
temperature effects on dose response
220, 222, 223

Magnetic resonance imaging (MRI)
brain tumor angiogenesis evaluation 52,
53, 61
correlation with methionine uptake
positron emission tomography,
low-grade gliomas 148–150
gamma knife treatment planning
accuracy 248, 249
image acquisition 250, 251
overview 247, 248
registration with other imaging
techniques 249
validation of frameless positron
emission tomography 251–253
MAGIC gel absorbed dose 215, 216,
218, 220
perfusion evaluation of brain tumors
areas of interest analysis 53
hemodynamic parameters 60, 61
perfusion ratios in malignant versus
benign tumors 55, 56, 61
principles 268
radiation therapy effects
study design 268
tumor progression group 275, 276
tumor regression group 275, 276
Magnetic resonance spectroscopy (MRS)
brain tumor evaluation
advantages 52
areas of interest analysis 53, 59, 60
grading of brain tumors 58, 59
metabolite ratios in malignant versus benign tumors 55–58, 61
principles 268
pulse sequences 60
radiation therapy effects
metabolite ratios 268, 275
study design 268
tumor progression group 275, 276
tumor regression group 275, 276
Meningioma, see also Sellar-parasellar tumors
Novalis system treatment
combined radiosurgery and radiotherapy 116
complications 119, 120
intensity-modulated stereotactic radiosurgery/radiotherapy 121
neurological outcomes 118
patient selection 120
study design 116, 117
tumor control 117–120
vision outcomes 120, 121
olfaction preservation in olfactory groove meningiomas, stereotactic radiosurgery
anosmia impact on patients 124, 125, 128, 129
case reports 125–127, 130, 131
conventional surgery outcomes 129, 130
olfactory system anatomy 127, 128
rationale 124, 125
Pituitary adenoma, see also Sellar-parasellar tumors
fractionated radiotherapy 135
gamma knife radiosurgery
advantages 140, 141
dose/energy calculations 165, 166
endocrinological control 136, 139, 140
hypopituitarism 140
mechanisms of action 167
side effects 137, 139
study design 135, 136

Morphology-guided planning, see Gamma knife
Neurofibromatosis type 2
acoustic neuroma, see Acoustic neuroma,
neurofibromatosis type 2
vestibular schwannoma, see Vestibular schwannoma
Normal tissue complication probability (NTCP)
calculation 67, 69
multiple brain tumor metastases prognosis 70, 74
Olfaction, see Meningioma
olfactory groove meningioma, see Meningioma
Pain
gamma knife management
cancer pain 165–168
dose/energy calculations 165, 166
indications 163, 164
mechanisms of action 167–169
overview 163
radiosurgery 163, 164
thalamic pain syndrome 165, 166, 168, 169
hypophysectomy
management of cancer pain 162, 163
mechanism of action 167
thalamic pain syndrome management 163
Pathology, see Radiosurgical pathology
Sellar-parasellar tumors
fractionated radiotherapy 135
gamma knife radiosurgery
advantages 140, 141
endocrinological control 136, 139, 140
hypopituitarism 140
side effects 137, 139
study design 135, 136
Pituitary adenoma, see also Sellar-parasellar tumors (continued)
gamma knife radiosurgery (continued)  
tumor control 136, 139
visual field changes 136, 137, 140
surgery risks 135
Polymer gel dosimetry, see also MAGIC applications 213, 226, 233, 234
  gamma knife treatment plan evaluation
    calibration and irradiation 226–228
dose distribution parameters 229, 233
  gel preparation 226
  nuclear magnetic resonance, absorbed
dose 228, 229, 233
  observed versus calculated values 231, 233, 234
  gel types 214
Positron emission tomography (PET)
  brain metastasis utility 48, 49
  fluorodeoxyglucose as tracer 47
  gamma knife treatment planning
    accuracy 248, 249
    image acquisition 250, 251
    overview 247, 248
  registration with other imaging
    techniques 249
  validation of frameless imaging
    251–253
  methionine uptake positron emission
tomography, evaluation of low-grade
gliomas after gamma knife surgery
dosimetry effects on metabolic course
    149
    follow-up and data analysis 146
  histology 143, 149
  magnetic resonance imaging correlation
    148–150
  metabolic activity evaluation
    147, 149–151
  patient characteristics 144, 145
  radiosurgery 145, 146
  principles 47
  radiation necrosis imaging 50
  study design 47
Quality assurance
  CyberKnife fiducial and skull tracking
    accuracy quality assurance
  importance 258, 259
  monthly test for fiducial tracking
    accuracy 256
  monthly test for skull tracking
    accuracy 256, 257
  outcomes 258
  overview 236, 237, 244
Quality assurance in radiosurgery/radiotherapy (QUASIR), see Stereotactic radiosurgery/radiotherapy analysis;
  Tomographic phantom analysis
Radiation tolerance
  definition 22
  spinal cord, see Spinal cord radiation tolerance
Radiosurgical pathology
  degenerative and proliferative changes in
  radiosurgery 18
  goals 14
  historical perspective 14–16
  radiolesion characteristics 16–18
  rationale 19
Schwannoma, see Vestibular schwannoma
Sellar-parasellar tumors, microsurgery
  versus gamma knife radiosurgery
  case characteristics 2
  control rates by tumor type 3, 4, 9
  craniopharyngioma 5, 9
dosimetry 2, 9
  germinoma 10
  meningioma 6, 10, 11
  optic nerve glioma 10, 11
  pilocytic astrocytoma case presentation
    6, 8
  pituitary adenoma 5, 6, 9
  radiosensitivity of tumors 9
  radiosurgery efficacy evaluation 3
  suprasellar germinoma case
    presentation 8
Skull base chordoma
  epidemiology 83
  Novalis system treatment
    combined radiosurgery and
    radiotherapy 83
    outcomes 85–89
    patient characteristics 83, 85

Subject Index
Stereotactic irradiation (STI), experimental device for cat studies
computed tomography 34, 36
device features 30
film dosimetry 33
phantom 30
stereotactic radiosurgery 31, 33
X-Knife software, comparison with film dosimetry 29, 33, 34, 36
Stereotactic radiation therapy (SRT)
Novalis system, treatment of meningiomas
combined radiosurgery and radiotherapy 116
complications 119, 120
intensity-modulated stereotactic radiosurgery/radiotherapy 121
neurological outcomes 118
patient selection 120
study design 116, 117
tumor control 117–120
vision outcomes 120, 121
Novalis system, treatment of skull base chordomas
combined radiosurgery and radiotherapy 83
outcomes 85–89
patient characteristics 83, 85
toxicity 88
treatment planning and delivery 85
Stereotactic radiosurgery/radiotherapy analysis (STERAS)
applications 244
goals 237
phantom, see Tomographic phantom analysis
test routines
L-test 242, 243
simulation patient 243
system test 240–242
Thalamic pain syndrome, see Pain
Tomographic phantom analysis (TOPAS)
applications 244
film dosimetry 239, 240
goals 237
phantom 237, 238
Trigeminal nerve radiosurgery, see Cluster headache; Trigeminal neuralgia
Trigeminal neuralgia
CyberKnife radiosurgery
computed tomographic cisternography 182
dose placement precision 184–187
image-guided radiosurgery 183, 184
pain relief and temporal patterns 185, 186, 188
patient selection 182
side effects 185
treatment planning 183, 187, 188
epidemiology 172
gamma knife radiosurgery 172, 176, 177, 182
Linac radiosurgery
complications 176
pain relapse 175, 176
patient selection 172
technique 172–175, 177, 178
response assessment 175
statistical analysis 175
medical therapy 172
Tumor control probability (TCP)
formula 67
multiple brain tumor treatment
treatment planning
prognosis
normal tissue complication probability, effects on survival time 70, 74
study design 68, 69
survival time prediction 68–70, 73, 74
whole-brain irradiation 67, 72, 73
Vestibular schwannoma
gamma knife radiosurgery and microsurgery for hearing preservation
Vestibular schwannoma
gamma knife radiosurgery and microsurgery for hearing preservation (continued) outcomes with and without microsurgery 109, 110, 112, 113 rationale 108 study design 108 large-tumor treatment 107, 108

Vision
optic apparatus dose absorption, radiosurgery of multiple brain metastases 78, 80 pituitary adenoma gamma knife radiosurgery effects 136, 137, 140 preservation with meningioma treatment 120, 121 Whole-brain irradiation, multiple brain metastases 67, 72, 73